Comparison of Dorzolamide-Timolol Fixed Combination and Latanoprost, Effects on Intraocular Pressure and Ocular Pulse Amplitude

Se Ran Jang; Mar Vin Lee; Jae Hong Ahn

doi:10.3341/jkos.2014.55.6.854

Journal List > J Korean Ophthalmol Soc > v.55(6) > 1009992

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Jang, Lee, and Ahn: Comparison of Dorzolamide-Timolol Fixed Combination and Latanoprost, Effects on Intraocular Pressure and Ocular Pulse Amplitude

Original Article

J Korean Ophthalmol Soc 2014;55(6):854-859.

Published online: 30 August 2014

DOI: https://doi.org/10.3341/jkos.2014.55.6.854

Comparison of Dorzolamide-Timolol Fixed Combination and Latanoprost, Effects on Intraocular Pressure and Ocular Pulse Amplitude

Se Ran Jang, MD¹, Mar Vin Lee, MD², Jae Hong Ahn, MD, PhD¹

¹Department of Ophthalmology, Ajou University Medical Center, Ajou University School of Medicine, Suwon, Korea

²Department of Ophthalmology, DMC BunDang Jesaeng General Hospital, Seongnam, Korea

Address reprint requests to Jae Hong Ahn, MD, PhD, Department of Ophthalmology, Ajou University Medical Center, #164 World cup-ro, Yeongtong-gu, Suwon 443-380, Korea, Tel: 82-31-219-5260, Fax: 82-31-219-5259, E-mail: chrisahn@ajou.ac.kr

Received 26 October 2013 Revised 4 January 2014 Accepted 1 May 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To compare dorzolamide-timolol fixed combination (DTFC) and latanoprost with regard to their effects on intraocular pressure (IOP) and ocular pulse amplitude (OPA).

Methods

Sixty eyes of 60 patients with open angle glaucoma or glaucoma suspect were included in the present study. Patients were divided into 2 groups, DTFC-treated (n = 30) and latanoprost-treated (n = 30). IOP and OPA were measured with dynamic contour tonometer (DCT) and Goldmann applanation tonometer (GAT), before and at least 1 month after treatment.

Results

GAT IOP, DCT IOP and OPA decreased by 2.25 ± 2.23 mm Hg, 1.97 ± 2.06 mm Hg, and 0.14 ± 0.88 mm Hg, re-spectively in the DTFC-treated group. In the latanoprost-treated group, GAT IOP, DCT IOP and OPA was reduced by 2.74 ± 2.96 mm Hg, 2.06 ± 3.50 mm Hg, and 0.69 ± 1.07 mm Hg, respectively. There was no significant difference (p = 0.311) in the decline of IOP between the 2 groups, but OPA of the DTFC-treated group decreased less than the latanoprost-treated group (p = 0.032).

Conclusions

No significant differences were observed in the short-term decline of IOP between the 2 medications. However, the influence of DTFC on OPA appeared negligible in the latanoprost-treated group.

Keywords: Dorzolamide-timolol fixed combination, Dynamic contour tonometer, Intraocular pressure, Latanoprost, Ocular

References

1. Casson RJ, Chidlow G, Wood JP, et al. Definition of glaucoma: clinical and experimental concepts. Clinical and Experimental Ophthalmology. 2012; 40:341–9.

2. Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow in glaucoma. Progress in Retinal and Eye Research. 2002; 21:359–3.

3. Dastiridou AI, Tsironi EE, Tsilimbaris MK, et al. Ocular rigidity, outflow facility, ocular pulse amplitude, and pulsatile ocular blood flow in open-angle glaucoma: a manometric study. Invest Ophthalmol Vis Sci. 2013; 54:4571–7.

4. Mousa AR, Bredetean V, Costin D. The role of ocular perfusion pressure in the course of primary open angle glaucoma in patients with systemic hypertension. Rev Med Chir Soc Med Nat Iasi. 2012; 116:162–7.

5. Costagliola C, Campa C, Parmeggiani F, et al. Effect of 2% dorzo-lamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol. Br J Clin Pharmacol. 2007; 63:376–9.

6. Kurashima H, Watabe H, Sato N, et al. Effects of prostaglandin F(2a) analogues on endothelin-1-induced impairment of rabbit oc-ular blood flow: comparison among tafluprost, travoprost, and latanoprost. Exp Eye Res. 2010; 91:853–9.

7. Georgopoulos GT, Diestelhorst M, Fisher R, et al. The short-term effect of latanoprost on intraocular pressure and pulsatile ocular blood flow. Acta Ophthalmol Scand. 2002; 80:54–8.

8. Janulevicienë I, Harris A, Kagemann L, et al. A comparison of the effects of dorzolamide/timolol fixed combination versus latano-prost on intraocular pressure and pulsatile ocular blood flow in pri-mary open-angle glaucoma patients. Acta Ophthalmol Scand. 2004; 82:730–7.

9. Zinkernagel MS, Ebneter A. Acetazolamide influences ocular pulse amplitude. J Ocul Pharmacol Ther. 2009; 25:141–4.

10. Haustein M, Spoerl E, Boehm AG. The effect of acetazolamide on different ocular vascular beds. Graefes Arch Clin Exp Ophthalmol. 2013; 251:1389–98.

11. Moon DRC, Ha SJ. Analysis of clinical effectiveness of tafluprost by ocular pulse amplitude. J Korean Ophthalmol Soc. 2013; 54:303–9.

12. Budenz DL. Glaucomatous visual field loss. In : Budenz DL, editor. Atlas of Visual Field. Lippincott-Raven Publishers;1997. p. 143–193.

13. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. Dorzolamide-Timolol Study Group. A randomized trial comparing the dorzola-mide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 1998; 105:1945–51.

14. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. Dorzolamide-Timolol Combination Study Group. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology. 1998; 105:1952–9.

15. Siesky B, Harris A, Kagemann L, et al. Ocular blood flow and oxy-gen delivery to the retina in primary open-angle glaucoma patients: the addition of dorzolamide to timolol monotherapy. Acta Ophthalmol. 2010; 88:142–9.

16. Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocu-lar hypertension. Arch Ophthalmol. 2003; 121:453–7.

17. Boltz A, Schmidl D, Weigert G, et al. Effect of latanoprost on cho-roidal blood flow regulation in healthy subjects. Invest Ophthalmol Vis Sci. 2011; 52:4410–5.

18. Kim TW, Kim M, Lee EJ, et al. Intraocular pressure-lowering effi-cacy of dorzolamide/timolol fixed combination in normal-tension glaucoma. J Glaucoma. 2014; 23:329–32.

19. Drance S, Anderson DR, Schulzer M. Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001; 131:699–708.

20. Pozarowska D. Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2010; 4:1229–36.

21. Stalmans I, Harris A, Vanbellinghen V, et al. Ocular pulse ampli-tude in normal tension and primary open angle glaucoma. J Glaucoma. 2008; 17:403–7.

22. Kaufmann C, Bachmann LM, Thiel MA. Comparison of dynamic contour tonometry with goldmann applanation tonometry. Invest Ophthalmol Vis Sci. 2004; 45:3118–21.

23. Haustein M, Spoerl E, Boehm AG. The effect of acetazolamide on different ocular vascular beds. Graefes Archive for Clinical & Experimental Ophthalmology. 2013; 251:1389–98.

24. Zinkernagel MS, Ebneter A. Acetazolamide influences ocular pulse amplitude. Journal of Ocular Pharmacology and Therapeutics. 2009; 25:141–4.

25. Tabuchi H, Kiuchi Y, Ohsugi H, et al. Effects of corneal thickness and axial length on intraocular pressure and ocular pulse amplitude before and after cataract surgery. Can J Ophthalmol. 2011; 46:242–6.

26. von Schulthess SR, Kaufmann C, Bachmann LM, et al. Ocular pulse amplitude after trabeculectomy. Graefes Archive for Clinical & Experimental Ophthalmology. 2006; 244:46–51.

27. Breusegem C, Fieuws S, Zeyen T, Stalmans I. The effect of trabe-culectomy on ocular pulse amplitude. Investigative Ophthalmology & Visual Science. 2010; 51:231–5.

Figure 1.

Change of ocular pulse amplitude (OPA) which was corrected by age and pretreatment intraocular pressure in lata-noprost (solid line) and dorzolamide-timolol fixed combination (DTFC, dotted line) groups OPA of latanoprost group de-creased more than that of DTFC group after treatment (p = 0.032, repeated measures ANOVA).

Table 1.

Characteristics of the patients in DTFC and Latanoprost groups

	DTFC (30 eyes of 30 patients)	Latanoprost (30 eyes of 30 patients)	p-value
Age (years)	41.9 ± 11.3	51.4 ± 13.2	0.004^*
Sex (male/female)	19/11	21/9	0.785^†
Spherical equivalent (diopter)	-2.846 ± 2.849	-1.629 ± 3.441	0.141^*
Pre-treatment GAT IOP (mm Hg)	16.3 ± 3.5	16.5 ± 3.3	0.850^*
Pre-treatment DCT IOP (mm Hg)	19.58 ± 2.99	19.96 ± 4.52	0.702^*
Pre-treatment OPA (mm Hg)	2.71 ± 1.53	3.09 ± 1.18	0.276^*
Visual acuity (decimal)	0.99 ± 0.04	0.95 ± 0.08	0.051^*
Corneal thickness (μm)	538.21 ± 34.39	529.43 ± 37.19	0.354^*
MD (dB)	-1.91 ± 4.51	-4.13 ± 6.87	0.144^*
PSD (dB)	3.80 ± 3.42	6.78 ± 5.47	0.014^*
Interval between pre- and post-treatment	39.9 ± 20.2	37.2 ± 15.1	0.565^*
Post-treatment GAT IOP (mm Hg)	13.9 ± 3.9	13.6 ± 3.4	0.777^*
Post-treatment DCT IOP (mm Hg)	17.60 ± 3.52	17.76 ± 3.17	0.851^*
Post-treatment OPA (mm Hg)	2.60 ± 1.53	2.35 ± 1.18	0.489^*

Values are presented as mean ± SD.

DTFC = dorzolamide-timolol fixed combination; GAT = goldmann applanation tonometer; IOP = intraocular pressure; DCT = dynamic contour tonometer; OPA = ocular pulse amplitude; MD = mean deviation; PSD = pattern standard deviation.

^* independent sample t-test;

^† χ²-test.

Table 2.

Change of IOP and OPA in each treatment group

	Mean difference in DTFC group	Mean difference in Latanoprost group	p-value^†
	(p-value)^*	(p-value)^*	p-value^†
GAT IOP	2.25 ± 2.23 (<0.001)	2.74 ± 2.96 (<0.001)	0.524
DCT IOP	1.97 ± 2.06 (<0.001)	2.06 ± 3.50 (0.002)	0.770
OPA	0.14 ± 0.88 (0.530)	0.69 ± 1.07 (0.001)	0.014

Values are presented as mean ± SD.

DTFC = dorzolamide-timolol fixed combination; GAT = goldmann applanation tonometer; IOP = intra ocular pressure; DCT = dynamic contour tonometer; OPA = ocular pulse amplitude.

^* Pre-treatment value-post-treatment value, paired sample t-test;

^† Comparison between groups, independent sample t-test.

Table 3.

Correlation between GAT IOP and OPA before and after treatment

Groups	OPA vs. GAT	OPA vs. GAT	Change of OPA vs.
Groups	Pre-treatment	Post-treatment	Change of GAT
Latanoprost	0.417 (0.022)	0.428 (0.018)	0.241 (0.199)
DTFC	0.735 (<0.001)	0.795 (<0.001)	0.174 (0.359)
Total patients	0.598 (<0.001)	0.649 (<0.001)	0.230 (0.078)

Pearson correlation coefficient (p-value).

GAT = goldmann applanation tonometry; IOP = intraocular pressure; OPA = ocular pulse amplitude; DTFC = dorzolamide-timolol fixed combination.

TOOLS

Similar articles